Bench to Boardroom Steering Group
Advisory Board
Lee Coney, HLS
Bobby Deal, Global Regulatory Services
Greer Deal, Global Regulatory Services
Sue Dunkerton, TWI
Jon Green, MedImmune
Martin Reilly, Fisher Scientific
Matthew Roe, Crescendo
Noel Smith, Lonza Biologics
Bobby Deal
Managing Director, Global Regulatory Services
A well connected visionary embracing new technologies and new markets, he started his career as an anaesthetic technician working as part of a team on the first heart and liver transplants at the world famous Addenbrooke's and Papworth hospitals. This kindled his interest in innovative medical solutions which today has translated into him becoming involved in the advances of stem cell therapy and regenerative medicine. In May 2008 he officially launched Global Regulatory Services (GRS), a specialist regulatory affairs consultancy to the Life Sciences. Combining his practical skills with his knowledge of global markets ensures companies plan at international level.
Lee Coney 
Chief Scientific Officer - Biologics
Lee was recruited by Huntingdon Life Sciences at the end of 2004 to take a leading role in handling enquiries from those customers developing biopharmaceutical products. Lee brought to the role 15 years hands-on experience of biopharmaceutical drug development gained in companies such as; Cantab Pharmaceuticals, Xenova and CellFactors. During his time in the biotechnology industry, he was involved in developing therapies including: vaccines, recombinant proteins; monoclonal antibodies; immunomodulatory molecules; viral and non-viral gene delivery systems; and cell-based therapies. He has a well-rounded knowledge of the regulatory environment for biopharmaceuticals and particular expertise in the analysis of protein and viral products.
In his current role Lee is responsible for ensuring that Huntingdon Life Sciences has the resources and expertise to support the modern biopharmaceutical industry. In addition he has a good understanding of the commercial reality of small to medium sized businesses, which can be helpful to those businesses.
Greer Deal
Director, Global Regulatory Services
During over 20 years experience in the Pharmaceutical Industry, Greer has gained inside knowledge of the workings of Medical and Regulatory Affairs Departments along with the commercial aspects of running a business. She is well known in the industry for being patient and clear headed under pressure. More recently, she co-founded Global Regulatory Services (GRS), a specialist regulatory affairs consultancy to the Life Sciences. Her personal passion is plant-based products and over the past few years she has gained a solid reputation in this niche area of the life sciences.
Sue Dunkerton, BSc, CEng, FIMMM
Co-Director of the HealthTech and Medicines Knowledge Transfer Network
Sue Dunkerton is Co-Director of the HealthTech and Medicines Knowledge Transfer Network (sponsored by the Technology Strategy Board), established to support and accelerate innovation in the life sciences sector for human health.
Sue has a background in materials engineering and, following a career spanning aerospace and electronics, moved into the medical sector around 1990. She has worked in the medical devices and technologies area predominantly, with more recent work in the KTN spanning assisted living, diagnosis for infectious agents and more recently regenerative and stratified medicine.
Sue works closely with UK government and particularly the Technology Strategy Board, to help represent business input to future technology and innovation strategy.
Sue sits on a number of bodies to support healthtech businesses in the UK, notably:
• Assisted Living Innovation Platform Steering Group
• Detection and Identification of Infectious Agents IP Steering Group
• BIS SME Competitiveness Working Group,
• NIHR Medical Devices Clinical Studies Working Group
• Institute of Materials Biomedical Applications Division
• EPSRC Strategic Advisory Team for Healthcare
• Medilink UK
Jon Green
VP, Business Operations, MedImmune
Jon held posts in academia as a member of scientific staff in the Biochemistry Department, Imperial College and then as a Senior Scientific Officer with the Medical Research Council. Jon joined Cambridge Antibody Technology, in 1992 as a Senior Scientist, initially working on several drug discovery projects before moving across to operational management. Jon now holds the post of VP Business Operations at what is now MedImmune, a wholly owned subsidiary of Astra Zeneca formed through the merger of CAT and MedImmune inc. Jon is responsible for leading the site operations of the Cambridge R & D facilities, with specific focus on property, engineering, laboratory and office facilities, security, EHS, procurement, and risk management. Jon is also currently Chairman of One Nucleus, the largest Life Sciences membership organisation in Europe and sits on the Steering committee of the Pharmaceutical Industry Security Forum. Jon has an MPhil in molecular biology, is a Chartered Biologist, a Fellow of the Society of Biology and a Fellow of the Royal Society of Arts and Manufacturing. Jon also is a member of the Security Institute the British Institute of Facilities Management and British Association of Research Quality Assurance.
Martin Reilly
Regional Sales Manager for Fisher Scientific in Central UK
Martin Reilly is the Regional Sales Manager for Fisher Scientific in Central UK, responsible for the team of Account Managers and Technical Specialists covering an area roughly comprising Oxford, Cambridge, as far south as the M25/M4 and up to Nottingham. Martin also manages the One Nucleus Preferred Supplier Agreement for Fisher Scientific nationally, and you can contact him on 07835 272753 if you would like to know more about the great benefits on offer through the contract.
Matthew Roe
Chief Business Officer, Crescendo Biologics
Matthew joined Crescendo in June 2011 from Genzyme Corporation where he was Senior Director, Business Development & Licensing.
During a 23-year career at Genzyme, Matthew was active in licensing, alliance management, acquisition, divestment, and sales and marketing, and saw the corporation develop from an entrepreneurial start-up to a leading multi-national biotechnology company. He negotiated and managed multiple agreements for drug delivery technologies in the USA, Europe and Japan and was also a core team member for the divestment of Genzyme's Pharmaceuticals business.
Noel Smith
Science Leader, Lonza
Noel graduated from the University of Wales, Cardiff and then went on to study for a PhD at the University of Cambridge where a portion of mhis PhD was carried out at GSK. IHe then followed my PhD with a PostDoc position also at the University of Cambridge before joining Lonza’s Applied Protein Services Department in January 2009. His current role as a Science Leader includes the design and development of novel in vitro immunological assays as well as routine screening assays for use in the design and development of protein therapeutics and vaccines.